BridgeBio Pharma Net Profit Margin 2018-2024 | BBIO

BridgeBio Pharma net profit margin from 2018 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
BridgeBio Pharma Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2024-09-30 $0.22B $-0.44B -200.92%
2024-06-30 $0.22B $-0.45B -206.85%
2024-03-31 $0.22B $-0.54B -245.66%
2023-12-31 $0.01B $-0.64B -6430.00%
2023-09-30 $0.01B $-0.61B -6130.00%
2023-06-30 $0.01B $-0.57B -9550.00%
2023-03-31 $0.08B $-0.43B -544.87%
2022-12-31 $0.08B $-0.48B -616.67%
2022-09-30 $0.09B $-0.49B -550.56%
2022-06-30 $0.09B $-0.51B -559.34%
2022-03-31 $0.07B $-0.60B -838.03%
2021-12-31 $0.07B $-0.56B -814.49%
2021-09-30 $0.06B $-0.54B -955.36%
2021-06-30 $0.06B $-0.50B -798.39%
2020-09-30 $0.02B $-0.40B -1827.27%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00